02493.HK
MABWELL-B
HKSE · Healthcare · Biotechnology · CN
HKD 20.78
+0.58%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +188.0%
- EBITDA
- +23.3%
- EBIT
- +8.4%
- Net income
- +7.1%
- EPS
- +6.9%
- Free cash flow
- +65.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026